Devrimsel Harika Ertem
Research Subjects
Research Interests
Devrimsel Harika Ertem has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Derya Uluduz
Department of Neurology, İstanbul University Cerrahpaşa- Cerrahpaşa Faculty of Medicine, İstanbul, Turkey
3 shared publicationsAyhan Bingol
Department of Neurology, İstanbul University Cerrahpaşa- Cerrahpaşa Faculty of Medicine, İstanbul, Turkey
2 shared publicationsAyhan Koksal
Bakırköy Research and Training Hospital for Neurologic and Psychiatric Diseases, Neurology Clinic, İstanbul, Turkey
2 shared publications- Faik Ilik
Department of Neurology, Elbistan State Hospital, Kahramanmaras, Turkey
2 shared publications - Faik İlIk
KTO Karatay University, Medical Faculty, Department of Neurology, Konya, Türkiye
2 shared publications - Hanife Saglam
Harvard Medical School, Boston, Massachusetts, United States of America
2 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (12) , 001-005
Pain on the stage: a historical-neurological analysis of Afife Jale, Türkiye's first Muslim actress
Afife Jale (1902–1941) was a revolutionary in Turkish history as the first Muslim woman to perform on the professional theater stage. Despite her cultural significance, her life was overshadowed by chronic, debilitating headaches, and a subsequent fatal struggle with substance use disorder. This historical reconstruction explores the intersection of her pioneer identity, the progression of her neurological condition, and the iatrogenic medical practices of the early 20th century. Historical accounts suggest that Jale may have experienced recurrent severe hemicranial pain, exacerbated by the sociopolitical stress of her era. Her exposure to morphine as a primary analgesic, a common practice of the period, may have contributed to a clinical evolution compatible with phenomena currently conceptualized as medication-overuse headache and opioid-induced hyperalgesia. Her decline and eventual death at age 39 illustrate the tragic consequences of failing to distinguish between physical pain and psychological trauma within the therapeutic paradigms of the early Republican era. Her story is a reminder that, despite new treatments for headache, iatrogenic addiction remains a serious risk. Honoring her legacy means committing to ethical, multidisciplinary pain management that protects both the health and the creative soul of every patient.
- 6 October 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (12) , 001-005
Open AccessPain on the stage: a historical-neurological analysis of Afife Jale, Türkiye's first Muslim actress
Afife Jale (1902–1941) was a revolutionary in Turkish history as the first Muslim woman to perform on the professional theater stage. Despite her cultural significance, her life was overshadowed by chronic, debilitating headaches, and a subsequent fatal struggle with substance use disorder. This historical reconstruction explores the intersection of her pioneer identity, the progression of her neurological condition, and the iatrogenic medical practices of the early 20th century. Historical accounts suggest that Jale may have experienced recurrent severe hemicranial pain, exacerbated by the sociopolitical stress of her era. Her exposure to morphine as a primary analgesic, a common practice of the period, may have contributed to a clinical evolution compatible with phenomena currently conceptualized as medication-overuse headache and opioid-induced hyperalgesia. Her decline and eventual death at age 39 illustrate the tragic consequences of failing to distinguish between physical pain and psychological trauma within the therapeutic paradigms of the early Republican era. Her story is a reminder that, despite new treatments for headache, iatrogenic addiction remains a serious risk. Honoring her legacy means committing to ethical, multidisciplinary pain management that protects both the health and the creative soul of every patient.
- 1 January 2026
- Published by Ideggyogyaszati Szemle Journal in Ideggyogyaszati Szemle
- Vol. 79 (1-2) , 45-52
The efficacy of Gasserian ganglion block and pulsed radiofrequency in the treatment of chronic cluster headache: A retrospective cohort study
Background and purpose To assess the effectiveness of Gasserian ganglion block and pulsed radiofrequency in managing chronic cluster headache (CCH). Methods We enrolled 38 patients with treatment-resistant CCH who were admitted between March 2020 and January 2024 and underwent Gasserian ganglion pulsed radiofrequency (PRF) combined with a ganglion block. Patients were followed up for six months, with pain severity assessed using the 0-10 Numerical Pain Rating Scale (NPRS). Results Among 38 patients (mean age 30.8 ± 8.6 years), the mean headache duration before treatment was 29.72 ± 17.65 months, and patients reported an average of 19.11 ± 2.01 headache days per month. Before the procedure, the mean NPRS score was 8.81 ± 0.80, which significantly decreased to 4.13 ± 3.74 post-treatment (p=0.001) and further declined to 3.38 ± 1.59 at the six-month follow-up (p=0.002). Four patients became pain-free, while 13 did not benefit from the procedure. The mean number of headache days dropped to 6.40 ± 4.22 per month (p<0.001). Additionally, 24 patients required lower doses or fewer preventive medications, suggesting a sustained therapeutic benefit. The procedure had mild and temporary side effects, including pain on the day of injection, and localized discomfort. No serious complications were reported. Conclusion Our results showed a significant reduction in pain and attack frequency with Gasserian ganglion block and PRF for treating CCH resistant to standard therapies, with many patients requiring less medication. The procedure was well-tolerated, with mild and temporary side effects; these findings suggest it may be a promising option for drug-resistant CCH. Future studies should include controlled trials for further evaluation.
- 1 January 2026
- Published by Ideggyogyaszati Szemle Journal in Ideggyogyaszati Szemle
- Vol. 79 (1-2) , 45-52
The efficacy of Gasserian ganglion block and pulsed radiofrequency in the treatment of chronic cluster headache: A retrospective cohort study
Background and purpose To assess the effectiveness of Gasserian ganglion block and pulsed radiofrequency in managing chronic cluster headache (CCH). Methods We enrolled 38 patients with treatment-resistant CCH who were admitted between March 2020 and January 2024 and underwent Gasserian ganglion pulsed radiofrequency (PRF) combined with a ganglion block. Patients were followed up for six months, with pain severity assessed using the 0-10 Numerical Pain Rating Scale (NPRS). Results Among 38 patients (mean age 30.8 ± 8.6 years), the mean headache duration before treatment was 29.72 ± 17.65 months, and patients reported an average of 19.11 ± 2.01 headache days per month. Before the procedure, the mean NPRS score was 8.81 ± 0.80, which significantly decreased to 4.13 ± 3.74 post-treatment (p=0.001) and further declined to 3.38 ± 1.59 at the six-month follow-up (p=0.002). Four patients became pain-free, while 13 did not benefit from the procedure. The mean number of headache days dropped to 6.40 ± 4.22 per month (p<0.001). Additionally, 24 patients required lower doses or fewer preventive medications, suggesting a sustained therapeutic benefit. The procedure had mild and temporary side effects, including pain on the day of injection, and localized discomfort. No serious complications were reported. Conclusion Our results showed a significant reduction in pain and attack frequency with Gasserian ganglion block and PRF for treating CCH resistant to standard therapies, with many patients requiring less medication. The procedure was well-tolerated, with mild and temporary side effects; these findings suggest it may be a promising option for drug-resistant CCH. Future studies should include controlled trials for further evaluation.
- Open Access
- 22 May 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (6) , 545
Still Relevant, Still Effective: A Retrospective Observational Cohort Study on Real-Life Use of Flunarizine in Episodic Migraine
Aim: New disease-specific and mechanism-based treatments for migraine that share good evidence of efficacy have recently been introduced. However, due to reimbursement problems with insurance companies and high costs, classical anti-migraine drugs continue to be used. The objective of this study was to assess the clinical efficacy and tolerability of flunarizine for the preventive treatment of episodic migraine without aura in a Turkish cohort, concentrating on alterations in headache frequency, pain intensity, and migraine-related disability as measured by MIDAS scores within a practical clinical environment. Methods: Clinical and demographic data of 243 patients with episodic migraine without aura (175 females, 68 males; mean age 33.9 years) were evaluated. Headache frequency, side effects of flunarizine, pain intensity, and MIDAS scores were recorded during initial and 3-month follow-up periods. Results: After three months of flunarizine treatment, significant improvements were observed in headache parameters. The mean Numeric Pain Rating Scale (NPRS) score, the mean MIDAS score, and the monthly migraine attack frequency declined significantly (all p values < 0.001). Adverse events were reported in 21.8% of patients, most commonly weight gain and tiredness, followed by mood changes, gastrointestinal symptoms, and numbness or tingling. Patients experiencing side effects were significantly older (p = 0.023), though side effects did not impact treatment efficacy. Regression analysis identified no significant predictors of disability improvement. Conclusion: Our results demonstrated that flunarizine had considerable short-term efficacy in decreasing the frequency of migraine attacks, alleviating headache severity, and reducing migraine-related disability among patients experiencing episodic migraine without aura. Although mild to moderate side effects were fairly prevalent, especially in older individuals, they did not compromise the effectiveness of the treatment. Notably, early adverse events occurring within the first two weeks resulted in treatment discontinuation for some patients, highlighting the necessity for vigilant monitoring during the initial phase of treatment.
- 22 May 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (6) , 545
Open AccessStill Relevant, Still Effective: A Retrospective Observational Cohort Study on Real-Life Use of Flunarizine in Episodic Migraine
Aim: New disease-specific and mechanism-based treatments for migraine that share good evidence of efficacy have recently been introduced. However, due to reimbursement problems with insurance companies and high costs, classical anti-migraine drugs continue to be used. The objective of this study was to assess the clinical efficacy and tolerability of flunarizine for the preventive treatment of episodic migraine without aura in a Turkish cohort, concentrating on alterations in headache frequency, pain intensity, and migraine-related disability as measured by MIDAS scores within a practical clinical environment. Methods: Clinical and demographic data of 243 patients with episodic migraine without aura (175 females, 68 males; mean age 33.9 years) were evaluated. Headache frequency, side effects of flunarizine, pain intensity, and MIDAS scores were recorded during initial and 3-month follow-up periods. Results: After three months of flunarizine treatment, significant improvements were observed in headache parameters. The mean Numeric Pain Rating Scale (NPRS) score, the mean MIDAS score, and the monthly migraine attack frequency declined significantly (all p values < 0.001). Adverse events were reported in 21.8% of patients, most commonly weight gain and tiredness, followed by mood changes, gastrointestinal symptoms, and numbness or tingling. Patients experiencing side effects were significantly older (p = 0.023), though side effects did not impact treatment efficacy. Regression analysis identified no significant predictors of disability improvement. Conclusion: Our results demonstrated that flunarizine had considerable short-term efficacy in decreasing the frequency of migraine attacks, alleviating headache severity, and reducing migraine-related disability among patients experiencing episodic migraine without aura. Although mild to moderate side effects were fairly prevalent, especially in older individuals, they did not compromise the effectiveness of the treatment. Notably, early adverse events occurring within the first two weeks resulted in treatment discontinuation for some patients, highlighting the necessity for vigilant monitoring during the initial phase of treatment.
- 1 January 2025
- Published by Ideggyogyaszati Szemle Journal in Ideggyogyaszati Szemle
- Vol. 78 (3-4) , 122-126
Management of migraine without aura in adolescents: The experience of flunarizine use in a Turkish cohort
Background and purpose – Flunarizine is a specific calcium antagonist and is frequently used in adults for the prophylactic treatment of migraine. The use of flunarizine may lead to somnolence and weight gain, depression, and rarely extrapyramidal symptoms in adults. However, studies detecting the efficacy and safety of flunarizine use in adolescents are limited. In the current study, the effectiveness of flunarizine for the management of migraine without aura in Turkish adolescents was evaluated. Methods – Forty-six patients with migraine without aura, receiving flunarizine 5mg per day were included. In this retrospective study, the medical records of the cases were examined. Visual Analog Scale (VAS) and MIDAS scores were compared to assess the efficacy of the 3 months treatment. Results – The mean age was 14.37±1.83 years. There was a significant improvement in the VAS and MIDAS scores of the patients at the end of the third month (p<0.05). Side effects were detected in 23.9% of the patients, and these symptoms were sedation in 8.7% of the patients, mood swings in 4.3%, and vomiting in 4.3% of them. None of the patients discontinued the treatment due to side effects. Conclusion – Although the advancement of migraine research and treatment is inevitable, our findings support that flunarizine should still be considered as an effective and tolerable treatment option in adolescent migraineurs.
- 1 January 2025
- Published by Ideggyogyaszati Szemle Journal in Ideggyogyaszati Szemle
- Vol. 78 (3-4) , 122-126
Management of migraine without aura in adolescents: The experience of flunarizine use in a Turkish cohort
Background and purpose – Flunarizine is a specific calcium antagonist and is frequently used in adults for the prophylactic treatment of migraine. The use of flunarizine may lead to somnolence and weight gain, depression, and rarely extrapyramidal symptoms in adults. However, studies detecting the efficacy and safety of flunarizine use in adolescents are limited. In the current study, the effectiveness of flunarizine for the management of migraine without aura in Turkish adolescents was evaluated. Methods – Forty-six patients with migraine without aura, receiving flunarizine 5mg per day were included. In this retrospective study, the medical records of the cases were examined. Visual Analog Scale (VAS) and MIDAS scores were compared to assess the efficacy of the 3 months treatment. Results – The mean age was 14.37±1.83 years. There was a significant improvement in the VAS and MIDAS scores of the patients at the end of the third month (p<0.05). Side effects were detected in 23.9% of the patients, and these symptoms were sedation in 8.7% of the patients, mood swings in 4.3%, and vomiting in 4.3% of them. None of the patients discontinued the treatment due to side effects. Conclusion – Although the advancement of migraine research and treatment is inevitable, our findings support that flunarizine should still be considered as an effective and tolerable treatment option in adolescent migraineurs.
- Open Access
- 3 February 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (5) , e32810
A study of the relationship between serum uric acid levels and pain in patients with migraine
Serum uric acid (SUA), the end product of purine metabolism acts as an antioxidant and is related to oxidative stress. It has been reported that SUA may be involved in the pathogenesis of neurodegenerative diseases including Alzheimer disease, Huntington disease, Parkinson disease, and multiple sclerosis. However, studies evaluating SUA levels in migraine are scarce. This study aimed to explore the relationship between pain characteristics and SUA levels in patients with migraine and compare SUA levels in migraine patients during a headache attack and headache-free period with those control groups. This prospective, cross-sectional study included 78 patients with migraine and 78 healthy subjects who were randomly selected from hospital personnel as the control group. Headache characteristics (duration of attack, pain intensity, and headache frequency) and sociodemographic features were recorded. The SUA level was measured once in the control group and twice in the migraine patients, during the migraine attack and headache-free periods. Although the SUA levels of the migraine group in the headache-free period were higher than those of the control group, the difference was not statistically significant. Gender was not significantly related to the change in SUA levels between the attack and headache-free period. When the correlation between age, duration of migraine, frequency, duration, and intensity of pain was evaluated; the difference between SUA levels in female migraine patients was weakly correlated with headache intensity, whereas male patients had a moderate correlation. (P < .05; R > 0.250, and R > 0.516, respectively). The difference in SUA level in the migraine attack period compared to the headache-free period showing a positive correlation with pain intensity suggested that SUA may have a role in migraine due to its antioxidant role.
- 3 February 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (5) , e32810
Open AccessA study of the relationship between serum uric acid levels and pain in patients with migraine
Serum uric acid (SUA), the end product of purine metabolism acts as an antioxidant and is related to oxidative stress. It has been reported that SUA may be involved in the pathogenesis of neurodegenerative diseases including Alzheimer disease, Huntington disease, Parkinson disease, and multiple sclerosis. However, studies evaluating SUA levels in migraine are scarce. This study aimed to explore the relationship between pain characteristics and SUA levels in patients with migraine and compare SUA levels in migraine patients during a headache attack and headache-free period with those control groups. This prospective, cross-sectional study included 78 patients with migraine and 78 healthy subjects who were randomly selected from hospital personnel as the control group. Headache characteristics (duration of attack, pain intensity, and headache frequency) and sociodemographic features were recorded. The SUA level was measured once in the control group and twice in the migraine patients, during the migraine attack and headache-free periods. Although the SUA levels of the migraine group in the headache-free period were higher than those of the control group, the difference was not statistically significant. Gender was not significantly related to the change in SUA levels between the attack and headache-free period. When the correlation between age, duration of migraine, frequency, duration, and intensity of pain was evaluated; the difference between SUA levels in female migraine patients was weakly correlated with headache intensity, whereas male patients had a moderate correlation. (P < .05; R > 0.250, and R > 0.516, respectively). The difference in SUA level in the migraine attack period compared to the headache-free period showing a positive correlation with pain intensity suggested that SUA may have a role in migraine due to its antioxidant role.
- Open Access
- 1 January 2020
- Published by Baycinar Tibbi Yayincilik in Ağrı - The Journal of The Turkish Society of Algology
- Vol. 34 (1) , 75-76
The role and impact of the headache nurse specialist
In the current paper, we aim to emphasize the pivotal role of the specialist headache nurse whose scope of work is clearly defined and detailed in western medical practice within tertiary care.
- 1 January 2020
- Published by Baycinar Tibbi Yayincilik in Ağrı - The Journal of The Turkish Society of Algology
- Vol. 34 (1) , 75-76
Open AccessThe role and impact of the headache nurse specialist
In the current paper, we aim to emphasize the pivotal role of the specialist headache nurse whose scope of work is clearly defined and detailed in western medical practice within tertiary care.
- Open Access
- 1 January 2020
- Published by Baycinar Tibbi Yayincilik in Ağrı - The Journal of The Turkish Society of Algology
- Vol. 32 (4) , 193-201
Factors Influencing Sexual Functions in Turkish Female Patients with Migraine
Recent studies have shown a more frequent occurrence of sexual dysfunction in patients with headache. The aim of this study was to assess the effects of demographic and clinical characteristics and psychiatric symptoms on sexual dysfunction in Turkish female patients with migraine. In all, 18 sexually active patients with episodic migraine (EM), 12 patients with chronic migraine (CM), and 22 healthy controls of similar age were enrolled in the study. A numeric rating scale was administered to assess pain intensity. The psychiatric symptoms and sexual function of all of the participants were evaluated using the Beck depression and anxiety scales and the Golombok-Rust Inventory of Sexual Satisfaction (GRISS). The mean GRISS subscale scores did not differ significantly between the migraine groups and the control group (all p values <0.05). A positive correlation was found between the duration of headache and GRISS subscales of noncommunication, dissatisfaction, vaginismus, and anorgasmia in EM patients. In addition, there was a negative correlation with the infrequency and avoidance subscales. No correlation was detected between the GRISS subscale scores and the demographic and clinical characteristics of the patients with CM, with the exception of the level of education. Higher pain intensity scores and the presence of anxiety or depression among the EM and CM patients significantly affected all of the subscale scores of the sexual function inventory. Although there was no relationship between migraine chronicity and sexual dysfunction, our data indicated that patient demographic characteristics, greater pain severity, and comorbidities of depression or anxiety were associated with greater sexual dysfunction among patients with EM and CM.
- 1 January 2020
- Published by Baycinar Tibbi Yayincilik in Ağrı - The Journal of The Turkish Society of Algology
- Vol. 32 (4) , 193-201
Open AccessFactors Influencing Sexual Functions in Turkish Female Patients with Migraine
Recent studies have shown a more frequent occurrence of sexual dysfunction in patients with headache. The aim of this study was to assess the effects of demographic and clinical characteristics and psychiatric symptoms on sexual dysfunction in Turkish female patients with migraine. In all, 18 sexually active patients with episodic migraine (EM), 12 patients with chronic migraine (CM), and 22 healthy controls of similar age were enrolled in the study. A numeric rating scale was administered to assess pain intensity. The psychiatric symptoms and sexual function of all of the participants were evaluated using the Beck depression and anxiety scales and the Golombok-Rust Inventory of Sexual Satisfaction (GRISS). The mean GRISS subscale scores did not differ significantly between the migraine groups and the control group (all p values <0.05). A positive correlation was found between the duration of headache and GRISS subscales of noncommunication, dissatisfaction, vaginismus, and anorgasmia in EM patients. In addition, there was a negative correlation with the infrequency and avoidance subscales. No correlation was detected between the GRISS subscale scores and the demographic and clinical characteristics of the patients with CM, with the exception of the level of education. Higher pain intensity scores and the presence of anxiety or depression among the EM and CM patients significantly affected all of the subscale scores of the sexual function inventory. Although there was no relationship between migraine chronicity and sexual dysfunction, our data indicated that patient demographic characteristics, greater pain severity, and comorbidities of depression or anxiety were associated with greater sexual dysfunction among patients with EM and CM.
- 1 October 2019
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 33, 154-157
Evaluation of burden and depression among caregivers of stroke patients: The role of percutaneous endoscopic gastrostomy feeding tube
- 1 October 2019
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 33, 154-157
Evaluation of burden and depression among caregivers of stroke patients: The role of percutaneous endoscopic gastrostomy feeding tube
- Open Access
- 17 September 2019
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 7 (3) , 139-145
Opioids and Migraine: Opioid Awareness and Frequency of Use among Turkish Migraineurs
Despite the inadequate evidence of effi cacy and safety of opioid use for the treatment of migraine, it has been reported that patients with moderate to severe migraine headaches are prescribed opioids. Migraineurs may experience serious health impacts from opioids such as headache-related disability, psychiatric and cardiovascular comorbidities. The reduction of the risk of opioid abuse and prevention of an opioid epidemic are important public health challenges. The aim of this study was to assess the awareness of opioid therapy for migraine and the frequency of use among Turkish patients with episodic and chronic migraine. Materials and methods: consecutive migraine patients were enrolled in this cross-sectional study. A semi-structured questionnaire was developed and used by the researchers to assess the patients’ awareness of an opiod treatment option and the frequency of use of opioids for migraine treatment. Results. One hundred two patients were enrolled, of which 72 had episodic migraine and 30 had chronic migraine. All subjects reported that they had not been offered or prescribed any kind of opioids by general practitioners and neurologists for their headache. Besides, only 7 % of patients declared that they had heard of opioid treatment for migraine but they had never consulted their doctors about its effects. Conclusions. Our fi ndings demonstrated that opioids were not preferred as an option for acute or preventive migraine treatment by Turkish migraineurs and their physicians. The reduction of opioid prescription will help to prevent the development of medication overuse and opiate-induced headaches and drug addiction.
- 17 September 2019
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 7 (3) , 139-145
Open AccessOpioids and Migraine: Opioid Awareness and Frequency of Use among Turkish Migraineurs
Despite the inadequate evidence of effi cacy and safety of opioid use for the treatment of migraine, it has been reported that patients with moderate to severe migraine headaches are prescribed opioids. Migraineurs may experience serious health impacts from opioids such as headache-related disability, psychiatric and cardiovascular comorbidities. The reduction of the risk of opioid abuse and prevention of an opioid epidemic are important public health challenges. The aim of this study was to assess the awareness of opioid therapy for migraine and the frequency of use among Turkish patients with episodic and chronic migraine. Materials and methods: consecutive migraine patients were enrolled in this cross-sectional study. A semi-structured questionnaire was developed and used by the researchers to assess the patients’ awareness of an opiod treatment option and the frequency of use of opioids for migraine treatment. Results. One hundred two patients were enrolled, of which 72 had episodic migraine and 30 had chronic migraine. All subjects reported that they had not been offered or prescribed any kind of opioids by general practitioners and neurologists for their headache. Besides, only 7 % of patients declared that they had heard of opioid treatment for migraine but they had never consulted their doctors about its effects. Conclusions. Our fi ndings demonstrated that opioids were not preferred as an option for acute or preventive migraine treatment by Turkish migraineurs and their physicians. The reduction of opioid prescription will help to prevent the development of medication overuse and opiate-induced headaches and drug addiction.